title: Comparative study of both versions of an immunoassay commercialized for therapeutic drug monitoring of adalimumab in rheumatoid arthritis.
abstract: OBJECTIVE
  To describe the results of the comparative study between both versions of an immunoassay commercialized for therapeutic drug monitoring of adalimumab (ADA) in rheumatoid arthritis (AR).
  
  
  METHODS
  140 samples of patients with RA treated with ADA 40mg every 14 days were analyzed by both versions of the test (V1 or previous and V2 or updated).
  
  
  RESULTS
  A good correlation was obtained by both versions. In general V2 provides higher results of ADA's concentration than V1 and presents greater precision in the range of concentrations for clinical decisions, adjusting for the real concentration of the drug in blood. In addition, V2 allows for complete automation, which simplifies the analysis and reduces significantly the variability.
  
  
  CONCLUSIONS
  ADA's monitoring with the updated version demonstrated to have technical significant advantages, constituting a more practical tool for therapeutic decisions in patients with RA.
authors.affiliation: Sección de Laboratorio, Hospital Marina Baixa, Villajoyosa, Alicante, España.
authors.forename: Francisca
authors.initials: F
authors.lastname: Llinares-Tello
authors.affiliation: Sección de Reumatología¸ Hospital Marina Baixa, Villajoyosa, Alicante, España. Electronic address: j.rosas.gs@gmail.com.
authors.forename: José
authors.initials: J
authors.lastname: Rosas
authors.affiliation: Servicio de Reumatología, Hospital Universitario Gregorio Marañón, Madrid, España.
authors.forename: Inmaculada
authors.initials: I
authors.lastname: de la Torre
authors.affiliation: Servicio de Reumatología, Hospital Universitario Gregorio Marañón, Madrid, España.
authors.forename: Lara
authors.initials: L
authors.lastname: Valor
authors.affiliation: CIO-Universidad Miguel Hernández, Elche, Alicante, España.
authors.forename: Xavier
authors.initials: X
authors.lastname: Barber
authors.affiliation: Sección de Reumatología¸ Hospital Marina Baixa, Villajoyosa, Alicante, España.
authors.forename: José Miguel
authors.initials: JM
authors.lastname: Senabre
mesh_terms: D000068879:Adalimumab; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D004334:Drug Administration Schedule; D016903:Drug Monitoring / Q000379:methods*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D006801:Humans; D015203:Reproducibility of Results
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000068879:Adalimumab
keywords: Adalimumab; Anti-adalimumab antibodies; Anticuerpos antiadalimumab; Enzime linked immunosorbent assay; Enzimoinmunoanálisis; Monitorización terapéutica de fármacos; Therapeutic drug monitoring